Also participating in this financing are new investors Dynamk Capital, Formic Ventures, and Labcorp, as well as existing investors HBM Genomics and Viking Global Investors.
In connection with the financing, Shaun Rodriguez, PhD, director of Life Science Research at Casdin Capital, will join the Xcellbio board of directors.
A portion of the financing proceeds will be utilized to further advance the production of Xcellbio's new cell manufacturing platform, the KALI Cell Foundry.
The platform will deliver unique capabilities to support the development of therapeutic products with improved potency and persistence as well as reduced cell exhaustion.
Powering these features are proprietary technologies and advanced machine learning algorithms that can, for example, mimic immunosuppressive tumor microenvironments through the tightly controlled modulation of gas pressures and oxygen concentrations.
Xcellbio's new manufacturing platform will complement the company's AVATAR and AVATAR AI systems, which have been deployed in more than 130 research and industry labs globally.
Studies conducted using AVATAR systems have been featured in leading peer-reviewed journals including Nature, Cancer Discovery, Cell Stem Cell, and the International Journal of Molecular Sciences, among others.
Xcellbio is a venture-backed company driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms.
The company's commercial instruments and AI-driven software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cell therapy manufacturing platform.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval